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Abstract
Background: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its
erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but
direct effects of Epo in human WAT have not been documented. We therefore investigated the effects of acute and
prolonged Epo exposure on human WAT in vivo.
Method: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT
biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha.
Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA. A new and highly specific antibody (A82, Amgen)
was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt,
STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec,
AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
Results: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of
Epo-R mRNA.
Conclusion: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in
humans does not exert direct effects in a subcutaneous WAT.
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Background
Erythropoietin (Epo), a glycoprotein produced in the
kidneys and known for its erythropoietic effects, is used
to treat nephrogenic anemia. Moreover, Epo receptors
(Epo-R) of alleged functionality have been identified in
numerous tissues [1]. In particular, data in mice suggest
high expression of Epo-R mRNA in spleen and in white
adipose tissue (WAT) [2].
Studies in end-stage renal disease (ERSD) patients
show that serum levels of triglycerides, total cholesterol,
and LDL decrease to normal levels after Epo treatment
[3–5], but acute administration of rHuEpo in healthy
subjects do not significantly affect lipid levels, although
a tendency to increased free fatty acid (FFA) levels have
been observed [6]. However, prolonged treatment to
healthy humans with an erythropoiesis-stimulating agent
(ESA) significantly increases serum FFA levels and hep-
atic lipid content [7].
In mice overexpressing the Epo gene, increased fat
oxidation and an up-regulation of genes involved in lipid
metabolism in skeletal muscle has been shown [8]. On
the other hand, mice with a lack of Epo-R, except for
the bone marrow, have a significantly higher body
weight, increased fat mass and increased serum TG
levels [2, 9]. Furthermore, a reduction in body weight
due to reduced WAT mass in obese mice is found after
Epo treatment [2, 8–11].
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The mechanism by which Epo regulates fat metabol-
ism and body weight is currently unknown. One explan-
ation could be an increase in resting energy expenditure
including fat oxidation [2], but only the former has been
documented in healthy human subjects [6, 7]. As regards
direct peripheral actions of Epo, there is no evidence to
support such effects in human skeletal muscle [12, 13].
The effect of Epo treatment on WAT in humans has so
far not been evaluated, but Epo-R protein and mRNA
has been detected in WAT from mice in addition to a
suppressive effect of Epo on fat accumulation and prea-
dipocyte differentiation and expansion in vitro [2, 14].
Epo administration in mice is also associated with induc-
tion of brown adipose tissue (BAT) like features in WAT
with increased mitochondrial content and uncoupling
[9]. Furthermore, adipocyte specific deletion of the
Epo-R in mice lead to obesity and decreased insulin
sensitivity [9]. In contradiction, specific knockdown of
the adipocyte Epo-R showed that Epo signaling at
physiological levels was not essential for WAT metab-
olism [15].
The aim of the current study was to evaluate both the
acute and prolonged effects of Epo treatment on human
subcutaneous WAT on; 1) Epo-R expression, 2) activa-
tion of Epo-R related signaling pathways, and 3) direct




Ten healthy young men (23 (20–28) years, 179 (173–192)
cm, and 77 (68–90) kg, median (range)) participated after
providing written informed consent, in adherence to the
declaration of Helsinki. The Local Ethical Committee of
Central Denmark Region (M-2008-0016) approved the
study and it was further registered at clinicaltrials.gov (M-
20080035). Results regarding whole body and skeletal
muscle metabolism from the same study have previously
been published [6].
Prolonged study
Eighteen healthy untrained men (placebo group: 23
(21–35) years, 183 (172–191) cm, and 80.1 (67.7–96.5)
kg; ESA group: 22 (19–29) years, 186 (177–198) cm, and
80.3 (70.7–102.5) kg, median (range)) were included after
receiving oral and written information and written in-
formed consent to participate, in accordance with the
declaration of Helsinki. This study was approved by
the Local Ethical Committee of Central Denmark Re-
gion (M-20110035) and registered at clinical trials
(NTC01320449). This study is part of a larger study
where the effects of erythropoietin and endurance
training on skeletal muscle and whole body metabolism
have been compared [7, 13, 16, 17].
Study design
Acute study
The subjects were in a single-blind, crossover design
randomized to receive placebo and rHuEpo on two oc-
casions with a 14-day wash-out period in-between. On
the experimental days, the subjects arrived fasting (from
10 pm the evening before, water allowed) at the clinical
research unit in the morning. Placebo (saline) or rHuEpo
(Epoietin alpha, Eprex, 400 IU/kg) were administered i.v.
and subcutaneous fat biopsies were collected 1 h post
administration from the abdomen by liposuction under
local anesthesia. Fat biopsies were cleaned from blood,
frozen in liquid nitrogen, and stored at −80 °C until fur-
ther analysis. The experiments were performed under
thermo neutral conditions (21–23 °C).
Prolonged study
Only subjects fulfilling the following criteria were in-
cluded in the study: maximal oxygen uptake (VO2max)
below 50 ml/min/kg, age between 18 and 35, body mass
index (BMI) between 18 and 29 kg/m2, normal blood
pressure <135/85, and a hematocrit <45 %. The subjects
were randomly assigned to either a placebo group (sa-
line, n = 9) or an Epo group (n = 9). The subjects were in
a single blinded manner treated with either an
erythropoiesis-stimulating agent (ESA) (Darbepoietin-α,
Aranesp, Amgen, Thousand Oaks, CA, USA) or placebo
(saline) for 10 weeks. ESA/placebo were administrated
subcutaneously once weekly and the ESA dose was
40 μg for the first 3 weeks and 20 μg for the remaining
7 weeks as previously detailed [7]. Subcutaneous fat bi-
opsies were collected from the abdomen with liposuc-
tion under local anesthesia, before and after the
10 weeks treatment. The biopsies were cleaned for
blood, frozen in liquid nitrogen, and stored at −80 °C
until further analysis. The procedure was performed
under thermo neutral conditions (21–23 °C). The partic-
ipants were instructed to refrain from hard physical ac-
tivity, alcohol intake, or dietary changes 3 days prior to
collection of the biopsies. On the day of biopsy collec-
tion the subjects arrived at the clinical research unit
after an overnight fast (water intake allowed). During the
study period the participants were informed not to
change their level of physical activity or dietary habits.
Epo-R mRNA analysis
Subcutaneous WAT from the subjects in the acute study
(placebo treatment), bone marrow, and K-562 cells were
used for RNA extraction using TRIzol (Gibco BRL, Life
Technologies, Roskilde, Denmark) and homogenized
with 1 tungsten bead (Qiagen, Germantown, MD, USA)
using a Mixer Mill. RNA was quantified by measuring
absorbance at 260 and 280 nm using a NanoDrop 8000
Spectrophotometer (Thermo Scientific Pierce, Waltham,
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ME, USA). Integrity of the RNA was checked by visual
inspection of the 2 ribosomal RNAs on an agarose gel.
cDNA was synthesized using a Verso cDNA kit (cat#
Ab-1453, Thermo Fischer Scientific, Waltham, MA,
USA) with random hexamer primers. The levels of Epo
receptor mRNA was investigated, b2microglobolin were
used as housekeeping gene. For Epo receptor PCR a
RealTime ready Assay (Roche Diagnostics Corporation,
9115 Hague Road, Indianapolis, IN 46250-0414 USA)
was used. In this assay the following primers were used:
Epo-R: 5′-GCATTGCTGATTTTGTCTGC-3′ and 5′-
AAATACTGCAAGGTTGTGGTTTC-3′ together with
a small Universal hydrolysis probe substituted with
Locked Nucleic Acids from Roche (no152). No amplifi-
cation was observed in negative control tubes (without
reverse transcription or with only water). The b2micro-
globulin PCR was performed as a SYBR-Green assay using
KAPA SYBR® FAST qPCR Kit (Kapa Biosystems, Inc. Wo-
burn, MA, USA) with primers: 5′-GAGGCTATCCAGCG-
TACTCC-3′ and 5′-AATGTCGGATGGATGAAACCC-3′.
The PCR-reactions were performed in duplicate in a
LightCycler 480 (Roche Applied Science) using the fol-
lowing protocol: EPO-receptor assay: One step at 95 °C
for 3 min., then 95 °C for 10 s., 60 °C for 30 s., and 72 °
C for 11 s. b2microglobulin assay: One step at 95 °C for
3 min., then 95 °C for 10 s., 60 °C for 20 s., and 72 °C
for 10 s, and finally a melting curve analysis was per-
formed (for the b2microglobulin assay). The increase in
fluorescence was measured in real time during the ex-
tension step. The relative gene expression was estimated
using the default “Advanced Relative Quantification”
mode of the software version LCS 480 1.5.0.39 (Roche
Applied Science).
Western blot analysis
Approximately 100 mg subcutaneous fat tissue was ho-
mogenized in homogenization buffer (Acute study:
20 mM HEPES, 10 mM NaF, 1 mM Na3VO4, 1 mM
EDTA, 5 % SDS, 50 μg/ml Soybean trypsin inhibitor,
4 μg/ml Leupepsin, 0.1 mM Benzamidine, 2 μg/ml Anti-
pain, and 1 μg/ml Pepstatin; Prolonged study: 50 mM
HEPES, 20 mM NaF, 2 mM Na3VO4, 5 mM EDTA, 5 %
SDS, HALT, 5 mM NAM, 10 μM TSA) on a Precellys 24
(Bertin technologies, Montigny-le-Bretonneux, France).
Hereafter, samples were thermo mixed at 37 °C and 500-
1000 rpm for 1 h, followed by centrifugation at 14,000 x
g for 20 min at room temperature. The homogenate was
carefully separated from the lipid layer by a syringe, snap
frozen, and centrifuged again, in order to purify the
homogenate even further. The homogenate was frozen
in liquid nitrogen and stored at -80 °C until further
analysis.
In short, western blotting was performed as follows;
10 μl homogenate was loaded onto a 4–15 % SDS gel
(Criterion TGX stain-free gels, Bio-Rad, Hercules, CA,
USA), followed by electro blotting onto a PVDF mem-
brane. The stain-free technology was used to ensure
equal loading [18]. Membranes were blocked with 2.5 %
skimmed milk for 2 h before the primary antibody was
added and incubated overnight at 4 °C. The following
primary antibodies were used: From Cell signaling, Dan-
vers, MA, USA; phospho-LYN (Thr507) (#2731), LYN
(#2732), phospho-Akt (Ser473) (#9271), phospho-Akt
(Thr308) (#9275), pan-Akt (#4691), phospho-p70S6k
(Thr389) (#9205), p70S6k (#9202), phospho-STAT5
(Thr694) (#9359), STAT5 (#9358), phospho-p38MAPK
(Thr180/Thr182) (#9211), p38MAPK (#9212), phospho-
HSL (Ser660, corresponding to Ser650 in humans)
(#4126), phospho-HSL (Ser563, corresponding to Ser552
in humans) (#4139), phospho-HSL (Ser565, correspond-
ing to Ser554 in humans) (#4137), HSL (#4107), ATGL
(#2138), HSP60 (#12165), SDHA (#11998), PDH
(#3205), VDAC (#4661), phosphor-AMPKα (Thr172)
(#2531), and PKA (#9624), from Abcam, Cambridge,
UK; CGI-58 (#ab183739), anti-β-actin (#ab8227), and
G0S2 (#ab80353), from Novus bio, Littleton, CO, USA;
Cidea (#NB100-94219), from Abnova, Atlanta, GA,
USA; Cidec (#H00063924-M07), from Millipore, Darm-
stadt, Germany; AMPKα pan (#07-181) and phospho-
ACC (Ser79) (#07-303), from Amgen, Thousand Oaks,
CA, USA; anti-Epo-R (#A82), from Southernbiotech,
Birmingham, AL, USA: HRP streptavidin (#7100-05),
from Santa Cruz, Dallas, TX, USA; G0S2 (#sc-133424),
and from Pierce antibody production, Thermo scientific,
Waltham, MA, USA; Perilipin (#PA1-1052). Following
several washes, the membrane was incubated with the
secondary antibody (donkey-anti-rabbit IgG, #NA934,
Amersham, GE Healthcare, Pittsburgh, PA, USA/goat-
anti-rabbit IgG, #sc-2054, Santa Cruz, Dallas, TX, USA)
for 1 h at room temperature. Proteins were visualized by
chemiluminescence detection system (Super signal dura
extended duration substrate, Pierce, Thermo Scientific,
Waltham, MA, USA/Clarity Western ECL substrate,
Bio-Rad, Hercules, CA, USA #170-2054) using a Chemi-
DocTM MP imaging system (BioRad, Hercules, CA,
USA). Precision Plus Protein All Blue Prestained Protein
Standard (BioRad, Hercules, CA, USA #1610373) was
used as molecular weight marker.
Haematoxylin/Eosin staining
To evaluate adipocyte morphology, selected WAT biop-
sies from the prolonged study was fixed in cold (4 °C)
4 % formaldehyde (pH 7.0) for 2 days and embedded in
paraffin, after which sections of 3 μm were obtained.
After de-waxing and rehydration, the sections were
stained with Haematoxylin and Eosin and examined
under an Olympus light microscope (Olympus BX50).
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Statistics
Due to a low sample size and non-normally distributed
data, a Wilcoxon signed-rank test was used to test for
treatment effect on intracellular signaling in the acute
study. Results are shown as median and 25 % and 75 %
percentiles. A two-way ANOVA was used to analyze re-
sults from the prolonged study, QQ-plots and plots of re-
siduals vs. the fitted values checked normality, and data
were log-transformed when not normally distributed. The
level of significance was set to p < 0.05. Results are pre-
sented as means ± SE. Statistical analyses were made in
STATA version 12 (StataCorp, Collage Station, TX, USA)
and graphical presentations were made in Sigmaplot ver-
sion 11.0 (Systat Software, San Jose, CA, USA).
Results
Epo-R mRNA and protein in subcutaneous WAT
Epo-R mRNA was detected in WAT from all subjects
(average ct level of 29.0 cycles), as well as in the positive
K-562 cells (ct level of 29.6 cycles). A slightly lower level
of Epo-R mRNA was observed in bone marrow (average
ct level of 29.3 cycles) (Fig. 1a).
No band corresponding to the Epo-R (59kD) was iden-
tified in any of the fat biopsies or the negative control
769-P cells (Amgen, Thousand Oaks, CA, USA), how-
ever a band was identified in the two positive controls,
K-562 (Abcam, Cambridge, UK) and UT-7/Epo cells
(Amgen, Thousand Oaks, CA, USA) (Fig. 1b + c).
Epo-R signaling in subcutaneous WAT
Western blot analysis was used to measure phosphoryl-
ation levels of pertinent proteins indicative of Epo-R
activation and signaling. Phosphorylation levels were
measured 1 h post placebo/rHuEpo treatment. Neither
p-Akt (Thr308, p = 0.915; Ser473, p = 0.244), p-STAT5
(p = 0.309), p-p70s6k (p = 0.405), p-LYN (p = 0.245), or
p-p38MAPK (p = 0.735) levels were significantly differ-
ent between placebo and rHuEpo treatment (Fig. 2).
Alterations in lipolysis after acute rHuEpo treatment
Acute rHuEpo administration did not induce any dif-
ferences in the phosphorylation levels of p-HSL
(Ser563, p = 0.259; Ser565, p = 0.892; Ser660, p = 0.480), p-
ACC (p = 0.132), p-Perilipin (p = 0.295), or p-AMPK (p =
0.665). Furthermore, total protein levels of G0S2 (p =
0.276) did not change (Fig. 3).
Alterations in lipolysis and markers of metabolism after
prolonged ESA treatment
Changes in both phosphorylation (Fig. 4) and total pro-
tein levels (Fig. 5) of proteins involved in lipolysis in adi-
pose tissue after prolonged treatment with ESA were
evaluated. We did not record changes in any of the pro-
teins analyzed (two-way ANOVA, interactions p > 0.05,
time effects p > 0.05, ESA effects p > 0.05).
Haematoxylin/Eosin staining of WAT after prolonged ESA
treatment
Selected WAT sections after prolonged treatment with
ESA were stained with haematoxylin/Eosin in order to
evaluate WAT morphology and visually evaluate adipo-
cyte size. Biopsies from 2 subjects in each group were
evaluated (Fig. 6), the morphology appeared normal and
Fig. 1 Epo-R protein in subcutaneous fat tissue. Epo-R gene expression (a) in human WAT from the acute study in the placebo situation.
b2microglobolin was used as housekeeping gene control. Western blot analysis against the Epo-R (b) and β-actin (c) in human abdominal
subcutaneous fat tissue. Positive controls; K-562 (Abcam) and UT-7/Epo cells (Amgen), negative control: 769-P cells (Amgen), bone marrow;
BM, blank; B, and marker; M. The expected size of the Epo-R and β-actin are indicated by an arrow
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adipocyte size did not change substantially during the
10 weeks of placebo/ESA treatment.
Alterations in mitochondrial proteins from WAT after
prolonged ESA treatment
Different mitochondrial proteins (VDAC, HSP90, PDH,
and SDHA) were measured before and after prolonged
ESA treatment in order to evaluate mitochondrial pro-
tein content, as an indirect measure of mitochondrial
biogenesis. None of these proteins changed in response
to prolonged ESA treatment (Fig. 7). The level of un-
coupling protein 1 (UCP1) was also measured as a
marker of BAT in the human subcutaneous adipose bi-
opsies. A band corresponding to UCP1 was detected in
rat BAT but not in our human WAT biopsies (data not
shown).
Discussion
Previous studies in mice have shown significant effects
of Epo treatment on adipose tissue lipolysis and total
body weight. In human studies, FFA levels is increased
both after acute and prolonged rHuEpo/ESA treatment
[6, 7]. However, the current study did not confirm either
acute or prolonged effects of rHuEpo/ESA treatment on
adipose tissue lipases and signaling pathways involved in
the regulation of lipolysis.
Epo-R mRNA and protein and activation of signaling
pathways in WAT
Mouse WAT contains a sizable amount of Epo-R mRNA
[2], and Epo treatment associates with phosphorylation
of Akt [9]. Moreover, mice lacking the Epo-R in non-
hematopoietic tissues exhibit significantly reduced phos-
phorylation levels of p38MAPK, ERK42/44, and PPARγ
[2]. Furthermore, phosphorylation of ERK42/44,
p38MAPK, and PPARγ in preadipocytes does not de-
pend on Epo-R expression under normal culture condi-
tions, but during adipocyte differentiation the expression
of Epo-R increases in concomitance with increased
phosphorylation of ERK42/44, p38MAPK, PPARγ, Akt,
and STAT5 [2, 19]. In our human study, we detected
higher Epo-R mRNA levels in WAT than in bone mar-
row and than previously found in human skeletal muscle
[13]. However, we were not able to measure any Epo-R
Fig. 2 Epo-R signaling after acute rHuEpo administration. Western blot analysis for activation of relevant signaling proteins downstream of the
Epo-R. Phosphorylation levels are measured 1 h post placebo/rHuEpo treatment, and normalized to the total levels of the given protein. The
median and 25 % and 75 % percentiles are shown for placebo (white bar) and rHuEpo treatment (gray bars). Two subjects were omitted from the
analysis due to inadequate homogenization, thus, n = 8. No statistical significant differences in phosphorylation levels were detected between
treatments using a Wilcoxon signed-rank test
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protein in subcutaneous WAT and no evidence of per-
tinent signaling cascades related to the Epo-R after acute
Epo exposure. Species and dosing differences could be
an explanation for these conflicting results.
Direct and indirect effects of Epo on lipolysis
The direct effects of Epo on lipolysis in WAT have not
previously been investigated. Adipose triglyceride lipase
(ATGL) converts triglycerides (TG) to diacylglycerol,
and hormone sensitive lipase (HSL) hydrolyses diacyl-
glycerol to monoacylglycerol, in the process of convert-
ing TG to FFA [20]. HSL and ATGL were not affected
by rHUEpo/ESA treatment in the current studies.
ATGL is primarily activated by protein-protein inter-
action with the co-activator comparative gene
identification-58 (CGI-58) [21]. G0/G1 switch gene 2
(G0S2) is identified as an inhibitor of ATGL. Inhibition
by G0S2 appears to be dominant to activation by CGI-
58 [22, 23]. In the current study, prolonged ESA treat-
ment did not affect protein levels of CGI-58., nor did
G0S2 change after acute or prolonged rHuEpo/ESA
treatment.
Different lipid droplet proteins are involved in the
regulation of lipolysis. Perilipin (PLIN1) regulates the
activity of ATGL and HSL and their access to lipid sub-
strates in the lipid droplet. Cidea and Cidec are negative
regulators of lipolysis and promote lipid droplet
stabilization and inhibit lipolysis by providing a barrier
around the lipid core [20]. No alteration in PLIN1 or
Cidea/Cidec was found in the current study.
Acetyl CoA Carboxylase (ACC) is involved in the
regulation of beta-oxidation. In its active state ACC cat-
alyzes the conversion of acetyl-CoA to malonyl-CoA,
which inhibits beta-oxidation. Phosphorylation levels of
ACC were not altered in the current studies. Insulin also
affects lipolysis, with increased insulin levels inhibiting
lipolysis and stimulating lipogenesis. Insulin levels were
not altered in response to either acute or prolonged
rHuEpo/ESA treatment [6, 7]. In addition, ESA treat-
ment did not result in a visual reduction in adipocyte
morphology evaluated from haematoxylin/eosin stain-
ing. It cannot be excluded that Epo can affect lipoly-
sis in other indirect ways not evaluated in the current
study.
Fig. 3 Lipolytic pathways after acute rHuEpo administration. Western blot analysis evaluating activation of different proteins involved in lipolysis.
Phosphorylation levels are measured 1 h post placebo/rHuEpo treatment, and normalized to the total levels of the given protein. The median
and 25 % and 75 % percentiles are shown for placebo (white bar) and rHuEpo treatment (gray bars). Two subjects were omitted from the analysis
due to inadequate homogenization, and 1–2 subjects because of shortage of homogenate, thus, n = 6–7. No statistical significant differences in
phosphorylation levels or total protein levels were detected between treatments using a Wilcoxon signed-rank test
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Fig. 4 Phosphorylation levels of pertinent proteins involved in lipolysis after prolonged ESA treatment. Western blot analysis of phosphorylation
levels of pertinent proteins related to lipolysis in adipose tissue. Biopsies were collected before (black bars) and after 10 weeks (gray bars) of
treatment with either placebo or ESA. Phosphorylation levels were normalized to the total protein level for the given protein. Furthermore, the
relative increases were measured and the placebo-baseline measurements were set to average 100 %. No effect of ESA treatment or time was
found for any of the measured phosphorylation levels (n = 9)
Fig. 5 Total protein levels of proteins involved in lipolysis after prolonged ESA treatment. Western blot analysis of pertinent proteins related to
lipolysis in adipose tissue. Biopsies were collected before (black bars) and after 10 weeks (gray bars) of treatment with either placebo or ESA. Data
were normalized to total protein level in the gel. Furthermore, the relative increases were measured and the placebo-baseline measurements
were set to average 100 %. No effect of ESA treatment or time was found for any of the measured proteins (n = 9)
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Epo and metabolic activity in white adipose tissue
High-dose Epo treatment to mice leads to pronounced
reductions in body weight and knock-down of the Epo-R
in non-hematopoietic tissues leads to dramatic eleva-
tions in WAT amount [2, 9]. In contradiction, specific
knock-down of the Epo-R in mice adipose tissue did not
affect either body weight or body composition [15]. In
support hereof, in the current prolonged human study
we did not observe any changes in weight or body com-
position [7].
Recently it was shown that Epo treatment leads to in-
creased AMPKα phosphorylation both in preadipocytes
and in WAT from diet-induced obese mice [24]. The in-
creased AMPKα activity changed the NAD+/NADH ra-
tio resulting in activation of Sirt1 followed by increased
deacetylation of PGC-1α. Thus, Epo could through acti-
vation of the AMPKα-Sirt1-PGC-1α pathway acts as an
energy sensor and modulate cellular redox state and
energy homeostasis in adipocytes [24]. In the current
study, AMPKα phosphorylation was not altered 1-h post
rHuEpo administration.
Alterations in body weight and the amount of WAT
could also be due to alterations in energy expenditure.
In a mouse model, Epo was shown to affected activity
levels, total oxygen consumption, and respiratory quo-
tient (RQ) [2]. The authors speculated that Epo could
directly stimulate the proopiomelanocortin (POMC)
neurons in the hypothalamus to induce α-melanocyt-
stimulating hormone production that exerts direct
effects on food intake and energy homeostasis [2]. In
support of this, adipose tissue specific deletion of Epo-R
in mice did not significantly alter whole-body energy ex-
penditure or RQ values [15]. Resting energy expenditure
significantly increased in the current studies, and fat oxi-
dation tended to be increased in relation to rHuEpo
treatment [6, 7]. The effect of Epo on POMC was not
Fig. 6 Haematoxylin/Eosin staining of WAT after prolonged ESA treatment. Haematoxylin/eosin staining of selected WAT samples from 2 subjects
treated with placebo and 2 with ESA for 10 weeks
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measured in our human studies, hence, we cannot con-
clude on the neurological effects.
Epo and mitochondrial content in white adipose tissue
Diet-induced obese mice treated with EPO exhibit in-
creased CytC, Cpt1, and PGC-1α mRNA levels indicat-
ing an increased mitochondrial biogenesis [9]. In
addition, Epo stimulation increases citrate synthase ac-
tivity and fatty acid oxidation in both adipocytes and
WAT from diet-induced obese mice [9]. Thus, Epo
seems to increase cellular mitochondrial respiration and
oxidative metabolism beyond its effects on increased
oxygen transport in these animal studies. However, pro-
longed ESA treatment to humans did not support the
hypothesis that ESA should induce alterations in mito-
chondrial content in humans.
In contradiction to WAT, BAT does not respond to
Epo treatment in mice models [9]. However, Epo treat-
ment seems to promote a BAT-like phenotype in WAT
in mice with increased gene expression of e.g. Cidea,
UCP1, UCP3, PPARα, and PGC-1α, resulting in mito-
chondrial biogenesis and increased uncoupled respir-
ation [9]. In the current study, UCP1, Cidea and Cidec
protein levels were not significantly altered after
10 weeks of ESA treatment, thus, ESA treatment does
not seem to induce browning of WAT in humans.
Conclusion
In contrast to alluring data in mice model, the present
human studies do not support direct effects of Epo on
adipose tissue lipases and signaling pathways involved in
the regulation of lipolysis. Although Epo-R mRNA was
detected in human WAT samples, this did not translate
into detectable Epo-R protein, which is compatible with
the absence of evidence of Epo-R signaling. However, it
has to be acknowledged that the sample size in the
current study is small and the variation substantial. It re-
mains to be tested whether prolonged administration of
Epo in supra-physiological amounts to human subjects
may affect adipose tissue similar to what has been ob-
served in animal studies.
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